Clinical trials: Adebrelimab (SHR-1316)
Muscular Invasive Bladder Cancer (MIBC)
Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)
In phase II, the main objective is to evaluate the efficacy of SHR-A2102 combined with Adebrelimab in the treatment of muscular invasive bladder cancer (MIBC); The main objective of phase III is to evaluate the efficacy of…
- Trial name
- NCT06879145
- Testing
- SHR-A2102；Adebrelimab
- Where
- China
- Volunteers
- 840 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Locally Advanced Gastric or Gastroesophageal Junction Cancer
Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer
This study was a randomized, double-blind, multi-center phase III clinical trial to evaluate the event-free survival (EFS) of Adebrelimab with S-1 and oxaliplatin versus placebo combined with S-1 and oxaliplatin, and to evaluate…
- Trial name
- NCT07522151
- Testing
- Adebrelimab plus S-1 and oxaliplatin, Adebrelimab blank preparation plus S-1 and oxaliplatin.
- Where
- China
- Volunteers
- 874 people
- Sponsor
- Shanghai Shengdi Pharmaceutical Co., Ltd
Limited-stage Small-cell Lung Cancer
A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC
This study is an open-label, multicenter, phase II clinical study designed to evaluate the preliminary efficacy, safety, and tolerability of SHR-7787 in combination with Adebrelimab in patients with limited-stage small cell lung…
- Trial name
- NCT07798947
- Testing
- SHR-7787 Injection, SHR-1316
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Triple Negative Breast Cancer
A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer
It is a randomized, open label, positive drug controlled, multicenter design Phase III clinical trial, aims to compare the efficacy and safety of SHR-A1811 combined with Adebrelimab and the treatment selected by the researchers…
- Trial name
- NCT07679360
- Testing
- Trastuzumab Rezetecan for Injection, Adebrelimab Injection, Capecitabine tablets
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Non-squamous Non-small Cell Lung Cancer
A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients
Evaluating the Efficacy and safety of Adebrelimab in Combination with Platinum-based Doublet Chemotherapy and SHR-8068 as First-line Therapy for Patients with Advanced or Metastatic NSCLC Carrying STK11/KEAP1/KRAS Mutations
- Trial name
- NCT06335355
- Testing
- Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin, Camrelizumab + Pemetrexed + Carboplatin, Adebrelimab + Pemetrexed + Carboplatin
- Where
- China
- Volunteers
- 401 people
- Sponsor
- Shanghai Shengdi Pharmaceutical Co., Ltd